Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits

Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits

Abstract Background As the selective inhibitor of BRAF kinase, vemurafenib exhibits effective antitumor activities in patients with V600 BRAF mutant melanomas. However, acquired drug resistance invariably develops after its initial treatment. Methods Immunohistochemical staining was performed to det...

Full description

Bibliographic Details
Main Authors: Jiaojiao Hao, Wenhua Fan, Yizhuo Li, Ranran Tang, Chunfang Tian, Qian Yang, Tianhua Zhu, Chaoliang Diao, Sheng Hu, Manyu Chen, Ping Guo, Qian Long, Changlin Zhang, Ge Qin, Wendan Yu, Miao Chen, Liren Li, Lijun Qin, Jingshu Wang, Xiuping Zhang, Yandong Ren, Penghui Zhou, Lijuan Zou, Kui Jiang, Wei Guo, Wuguo Deng
Format: Article
Language:English
Published: BMC 2019-02-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Melatonin
Vemurafenib
NF-κB
iNOS
hTERT
Cancer stem cell
Online Access:http://link.springer.com/article/10.1186/s13046-019-1036-z

Internet

http://link.springer.com/article/10.1186/s13046-019-1036-z

Similar Items